These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17645871)

  • 21. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B; Duvillard L; Brindisi MC; Gautier E; Krempf M; Costet P; Cariou B
    Atherosclerosis; 2011 Nov; 219(1):342-8. PubMed ID: 21889145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects.
    Kappelle PJ; Lambert G; Dahlbäck B; Nielsen LB; Dullaart RP
    Atherosclerosis; 2011 Feb; 214(2):492-4. PubMed ID: 21122852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating PCSK9 levels correlate with the serum LDL cholesterol level in newborn infants.
    Araki S; Suga S; Miyake F; Ichikawa S; Kinjo T; Yamamoto Y; Kusuhara K
    Early Hum Dev; 2014 Oct; 90(10):607-11. PubMed ID: 25134067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol.
    Piper DE; Jackson S; Liu Q; Romanow WG; Shetterly S; Thibault ST; Shan B; Walker NP
    Structure; 2007 May; 15(5):545-52. PubMed ID: 17502100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.
    Kappelle PJ; Lambert G; Dullaart RP
    Atherosclerosis; 2011 Feb; 214(2):432-5. PubMed ID: 21122860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Leptin Replacement on PCSK9 in ob/ob Mice and Female Lipodystrophic Patients.
    Levenson AE; Haas ME; Miao J; Brown RJ; de Ferranti SD; Muniyappa R; Biddinger SB
    Endocrinology; 2016 Apr; 157(4):1421-9. PubMed ID: 26824363
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer.
    Ozkan C; Akturk M; Altinova AE; Cerit ET; Gulbahar O; Yalcin MM; Cakir N; Balos Toruner F
    Endocr J; 2015; 62(12):1091-9. PubMed ID: 26490048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population.
    Cui Q; Ju X; Yang T; Zhang M; Tang W; Chen Q; Hu Y; Haas JV; Troutt JS; Pickard RT; Darling R; Konrad RJ; Zhou H; Cao G
    Atherosclerosis; 2010 Dec; 213(2):632-6. PubMed ID: 21040917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [PCSK9: Structure and function. PCSK9 and low-density lipoprotein receptor. Mutations and their effects].
    Pedro-Botet J; Badimón L
    Clin Investig Arterioscler; 2016 May; 28 Suppl 2():3-8. PubMed ID: 27888903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.
    Maxwell KN; Breslow JL
    Proc Natl Acad Sci U S A; 2004 May; 101(18):7100-5. PubMed ID: 15118091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels.
    Abujrad H; Mayne J; Ruzicka M; Cousins M; Raymond A; Cheesman J; Taljaard M; Sorisky A; Burns K; Ooi TC
    Atherosclerosis; 2014 Mar; 233(1):123-9. PubMed ID: 24529132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis.
    Chen SN; Ballantyne CM; Gotto AM; Tan Y; Willerson JT; Marian AJ
    J Am Coll Cardiol; 2005 May; 45(10):1611-9. PubMed ID: 15893176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.
    Lambert G; Ancellin N; Charlton F; Comas D; Pilot J; Keech A; Patel S; Sullivan DR; Cohn JS; Rye KA; Barter PJ
    Clin Chem; 2008 Jun; 54(6):1038-45. PubMed ID: 18436719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma proprotein convertase subtilisin/kexin type 9: a marker of LDL apolipoprotein B-100 catabolism?
    Chan DC; Lambert G; Barrett PH; Rye KA; Ooi EM; Watts GF
    Clin Chem; 2009 Nov; 55(11):2049-52. PubMed ID: 19713274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.
    Kwakernaak AJ; Lambert G; Dullaart RP
    Clin Biochem; 2012 Nov; 45(16-17):1522-4. PubMed ID: 22809551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.
    Zhao Z; Tuakli-Wosornu Y; Lagace TA; Kinch L; Grishin NV; Horton JD; Cohen JC; Hobbs HH
    Am J Hum Genet; 2006 Sep; 79(3):514-23. PubMed ID: 16909389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relation of resistin to proprotein convertase subtilisin-kexin type 9 levels in coronary artery disease patients with different nutritional status.
    Li S; Xu RX; Zhang Y; Guo YL; Zhu CG; Liu G; Dong Q; Li JJ
    J Endocrinol Invest; 2015 Dec; 38(12):1291-9. PubMed ID: 26003826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury.
    Le Bras M; Roquilly A; Deckert V; Langhi C; Feuillet F; Sébille V; Mahé PJ; Bach K; Masson D; Lagrost L; Costet P; Asehnoune K; Cariou B
    J Clin Endocrinol Metab; 2013 Apr; 98(4):E732-6. PubMed ID: 23450051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
    Allard D; Amsellem S; Abifadel M; Trillard M; Devillers M; Luc G; Krempf M; Reznik Y; Girardet JP; Fredenrich A; Junien C; Varret M; Boileau C; Benlian P; Rabès JP
    Hum Mutat; 2005 Nov; 26(5):497. PubMed ID: 16211558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia.
    Leren TP
    Clin Genet; 2004 May; 65(5):419-22. PubMed ID: 15099351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.